BIO looks to re­struc­ture, lay­ing off staff amid chal­lenge to the trade org's nor­mal face-to-face style

The bio­phar­ma in­dus­try, on the whole, had a red-let­ter year in 2020 amid Covid-19, with fundrais­ing at an all-time high and ma­jor play­ers speed­ing vac­cines ahead to ap­proval. But for BIO, the in­dus­try’s lead­ing trade or­ga­ni­za­tion, the pan­dem­ic has prompt­ed a re­con­sid­er­a­tion of the game plan.

BIO will piv­ot to dig­i­tal as the Covid-19 pan­dem­ic con­tin­ues to rage, mak­ing “some staff re­duc­tions” as it looks to bring its rough­ly 37,000 in-per­son meet­ings each year to the web, the or­ga­ni­za­tion said Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER